Cancer Immunology Immunotherapy

Founding Editor
G. Mathé

Other Biological Response Modifications

Volume 24 1987

Editors in Chief

R. W. Baldwin **E. Mihich**

Editorial Board

R. Arnon Rehovot
R. Bast Durham
N. Bloksma Utrecht
T. Boon Brussels
E. C. Borden Madison
V. S. Byers Berkeley
T. Carey Ann Arbor
M. Cheever Seattle
M. Colnaghi Milan
G. A. Currie Oxted, Surrey
W. Den Otter Utrecht
S. Dray Chicago
S. Eccles Sutton, Surrey
I. Fidler Houston
A. Goldstein Washington
E. Grimm Houston
K. Hellström Seattle
J. Kieler Copenhagen
H. Kirchner Heidelberg
H. Kobayashi Sapporo
M. Mastrangelo Philadelphia
J. McVie Amsterdam
M. Micksche Vienna
P. Minden La Jolla
M. Mitchell Los Angeles
R. J. North Saranac Lake
H. Ozer Buffalo
G. Parmiani Milan
H. M. Pinedo Amsterdam
T. J. Priestman Birmingham
R. Rees Sheffield
P. Rümke Amsterdam
D. Scott Rochester
K. Sikora London
G. Stevenson Southampton
F. Vánky Stockholm
B. Vose Cheshire
Y. Yagi Kamakura City

Springer International

Cancer Immunology Immunotherapy

Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé
Editors: R. W. Baldwin, E. Mihich
Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page, or a minimum of US $ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß

© Springer-Verlag Berlin Heidelberg 1987

Contents of volume 24

No. 1 (pp 1– 92) published 12 February 1987
No. 2 (pp 93–184) published 14 April 1987
No. 3 (pp 185–274) published 22 May 1987

Agah R, Shau H, Mazumder A: Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations 247
Akiyoshi T, Arinaga S, Tsuji H: Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C 259
Aquino A → Tentori L, et al. 86
Arinaga S → Akiyoshi T, et al. 259
Azuma I → Matsuzaki T, et al. 99

Bakke A → Fujimiya Y, et al. 213
Ballatore P → Tentori L, et al. 86
Barlai-Kovach M → Kradin RL, et al. 76
Bártek J → Munzarová M, et al. 272
Beierwaltes WH → Wahl RL, et al. 221
Berry J, Green BJ, Matheson DS: Modulation of natural killer cell activity in stage I postmenopausal breast cancer patients on low-dose aminoglutethimide 72
Bettetini D → Pommier GJ, et al. 225
Bloksma N, Hofhuis FMA: Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A:U against solid Meth A tumors in mice 165
Bohy J → Dazord L, et al. 263
Bonmassar E → Tentori L, et al. 86
Böök K → Vánky F, et al. 180
Bourel D → Dazord L, et al. 263
Bourguet P → Dazord L, et al. 263
Boyle LA → Kradin RL, et al. 76
Brandon DR → Corvalan JRF, et al. 133
Brandon DR → Corvalan JRF, et al. 138
Bröcker E-B → Matzku S, et al. 151
Brüggen J → Matzku S, et al. 151
Bubeník J, Indrová M: The anti-tumour efficacy of human recombinant interleukin 2: Correlation between sensitivity of tumours to the cytolytic effect of LAK cells in vitro and their susceptibility to interleukin 2 immunotherapy in vivo 269
Budzynski W, Chirigos M, Gruys E: Augmentation of natural cell activity in tumor-bearing and normal mice by MVE-2 253
Bugelski PJ, Kirsh R, Buscarino C, Corwin SP, Poste G: Recruitment of exogenous macrophages into metastases at different stages of tumor growth 93
Burns C → Hersey P, et al. 144
Buscarino C → Bugelski PJ, et al. 93

Callahan RJ → Kradin RL, et al. 76
Canevari S → Ripamonti M, et al. 13
Canti G, Ricci L, Marelli O, Franco P, Nicolin A: Adoptive immunity in mice challenged with L1210/DTIC clones 64
Chang W-C → Fujimiya Y, et al. 213
Cheresh DA → Hersey P, et al. 144
Childs LR → Levin LV, et al. 202
Chirigos M → Budzynski W, et al. 253
Colnaghi MI → Ripamonti M, et al. 13
Corvalan JRF, Smith W: Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids 127
Corvalan JRF, Smith W, Gore VA, Brandon DR: Specific in vitro and in vivo drug localisation to tumour cells using a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids 133
Corvalan JRF, Smith W, Gore VA, Brandon DR, Ryde PJ: Increased therapeutic effect of vinca alkaloids targeted to tumour by a hybrid-hybrid monoclonal antibody 138
Corwin SP → Bugelski PJ, et al. 93
Culouscou JM → Pommier GJ, et al. 225
Cumber AJ → Eccles SA, et al. 37
Cunningham RE → Leong SPL, et al. 106

D'Atri S → Tentori L, et al. 86
Davis S → Levin LV, et al. 202
Dazord L, Bourel D, Martin A, Lecorre R, Bourguet P, Bohy J, Saccavini J-C, Delaval P, Louvet M, Toujas L: A monoclonal antibody (Po66) directed against human lung squamous cell carcinoma. Immunolocalization of tumour xenografts in nude mice 263
Dean CJ → Eccles SA, et al. 37
Delaval P → Dazord L, et al. 263
Den Otter W → De Weger RA, et al. 25
De Vecchis L → Tentori L, et al. 86
De Weger RA, Wilbrink B, Moberts RMP, Mans D, Oskam R, Den Otter W: Immune reactivity in SL2 lymphoma-bearing mice compared with SL2-immunized mice 25
Dubinett S → Kradin RL, et al. 76

Eccles SA, McIntosh DP, Purvies HP, Cumber AJ, Parnell GD, Forrester JA, Styles JM, Dean CJ: An ineffective monoclonal antibody-ricin A chain conjugate is converted to a tumouricidal agent in vivo by subsequent systemic administration of ricin B chain 37
Einhorn N → Einhorn S, et al. 190
Einhorn S, Ling P, Einhorn N, Strander H, Wasserman J: Influence of α-interferon therapy on blood lymphoid cells. Studies on antibody production, mixed lymphocyte culture response, mitogen responsiveness and 2'–5'oligoadenylate synthetase activity 190
Endo Y → Uchida H, et al. 207

Fitzgerald J → Wu J, et al. 68
Forrester JA → Eccles SA, et al. 37
Franco P → Canti G, et al. 64
Fuggetta MP → Tentori L, et al. 86
Fujimiya Y, Chang W-C, Bakke A, Horwitz D, Pattengale PK: Natural killer (NK) cell immunodeficiency in patients with chronic myelogenous leukemia. II. Successful cloning and amplification of natural killer cells 213
Fujiwara H → Yoshioka T, et al. 8
Fujiwara H, Sato S, Kosugi A, Fukuzawa M, Hamaoka T: Studies on the recovery from tolerance to tumor antigens. I. Bone marrow cells from tolerant hosts are not rendered tolerant, but provide potential to reconstitute tumor-specific effector T cell clones 113
Fujiwara H → Sato S, et al. 121
Fukuzawa M → Fujiwara H, et al. 113

Garrouste FL → Pommier GJ, et al. 225
Gochnour D → Rinehart J, et al. 244
Gore VA → Corvalan JRF, et al. 133
Gore VA → Corvalan JRF, et al. 138
Gorelik E → Peppoloni S, et al. 49
Grazioli L, Sensi M, Parmiani G: Defective T helper activity in the spleen of BALB/c mice immune to a syngeneic fibrosarcoma 237
Green BJ → Berry J, et al. 72
Griffin TW → Levin LV, et al. 202
Gruys E → Budzynski W, et al. 253

Haagensen DE, Jr → Levin LV, et al. 202
Hamaoka T → Yoshioka T, et al. 8
Hamaoka T → Fujiwara H, et al. 113
Hamaoka T → Sato S, et al. 121

Hashimoto S, Nomoto K, Nagaoka M, Yokokura T: In vitro and in vivo release of cytostatic factors from *Lactobacillus casei*-elicited peritoneal macrophages after stimulation with tumor cells and immunostimulants 1
Herberman RB → Peppoloni S, et al. 49
Hersey P, MacDonald M, Burns C, Cheresh DA: Enhancement of cytotoxic and proliferative responses of lymphocytes from melanoma patients by incubation with monoclonal antibodies against ganglioside GD_3 144
Hofhuis FMA → Bloksma N 165
Hong WS → Ishihara J, et al. 185
Hoon DSB, Ramshaw IA: A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic 42
Horwitz D → Fujimiya Y, et al. 213
Hoshi A → Ishihara J, et al. 185

Iigo M → Ishihara J, et al. 185
Indrová M → Bubeník J 269
Inoue K → Naito M, et al. 158
Ishihara J, Saijo N, Sasaki Y, Nakano H, Ozaki A, Takahashi H, Sakurai M, Nakagawa K, Iigo M, Kanzawa F, Hoshi A, Hong WS, Jett JR, Takahashi T: The different effects of recombinant human tumor necrosis factor on rat fibrosarcoma sublines 185
Ivert T → Vánky F, et al. 180

Jeglum KA → Steplewski Z, et al. 197
Jennings PA → Nelson M, et al. 231
Jett JR → Ishihara J, et al. 185

Kamiya H → Uchida H, et al. 207
Kanzawa F → Ishihara J, et al. 185
Kataoka T → Oh-hashi F, et al. 57
Kirsh R → Bugelski PJ, et al. 93
Klein E → Vánky F, et al. 180
Kosugi A → Fujiwara H, et al. 113
Kosugi A → Sato S, et al. 121
Kovařík J → Munzarová M, et al. 272
Kradin RL, Boyle LA, Preffer FI, Callahan RJ, Barlai-Kovach M, Strauss HW, Dubinett S, Kurnick JT: Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer 76
Kreicbergs A → Vánky F, et al. 180
Kuchroo VK → Nelson M, et al. 231
Kudo I → Naito M, et al. 158
Kurnick JT → Kradin RL, et al. 76

LaForge J → Rinehart J, et al. 244
Lange W → Masihi KN, et al. 19
Langvad E → Pedersen L, et al. 178
Lecorre R → Dazord L, et al. 263
Leong SPL, Noguchi PD, Cunningham RE, Takami T, Roth JA: Heterogenous expression of a murine B16 melanoma-associated antigen correlates with cell cycle 106
Levin LV, Griffin TW, Childs LR, Davis S, Haagensen DE, Jr: Comparison of multiple anti-CEA immunotoxins active against human adenocarcinoma cells 202
Lichtenstein A: Antitumor effect of the streptococcal preparation OK-432 in a murine model of ovarian cancer 172
Liebert M → Wahl RL, et al. 221
Ling P → Einhorn S, et al. 190
Louvet M → Dazord L, et al. 263

MacDonald M → Hersey P, et al. 144
Mans D → De Weger RA, et al. 25
Marelli O → Canti G, et al. 64
Martin A → Dazord L, et al. 263
Masihi KN, Lange W, Rohde-Schulz B: Modulation of natural killer cytotoxicity by muramyl dipeptide and trehalose dimycolate incorporated in squalane droplets 19
Matheson DS → Berry J, et al. 72
Mathieson BJ → Peppoloni S, et al. 49
Matsuzaki T, Yokokura T, Azuma I: Antimetastatic effect of *Lactobacillus casei* YIT9018 (LC 9018) on a highly metastatic variant of B16 melanoma in C57BL/6J mice 99
Matzku S, Brüggen J, Bröcker E-B, Sorg C: Criteria for selecting monoclonal antibodies with respect to accumulation in melanoma tissue 151
Mazumder A → Agah R, et al. 247
McIntosh DP → Eccles SA, et al. 37
Ménard S → Ripamonti M, et al. 13
Mezzanzanica D → Ripamonti M, et al. 13
Miotti S → Ripamonti M, et al. 13
Moberts RMP → De Weger RA, et al. 25
Mukai-Sato Y → Naito M, et al. 158
Munzarová M, Zemanová D, Kovařík J, Pačovský Z, Rejthar A, Bártek J: Expression of HLA-DR antigens on tumour cells does not contribute to skin reactivity to autologous cholesteryl hemisuccinate (CHS)-treated tumour cells in patients with metastatic melanoma 272

Nagaoka M → Hashimoto S, et al. 1
Naito M, Kudo I, Mukai-Sato Y, Tsushima S, Nomura H, Nojima S, Inoue K: Activation of mouse peritoneal macrophages by synthetic glyceroglycolipid liposomes 158
Nakagawa K → Ishihara J, et al. 185
Nakano H → Ishihara J, et al. 185
Neidhart J → Rinehart J, et al. 244
Nelson DS → Nelson M, et al. 231
Nelson M, Nelson DS, Kuchroo VK, Spradbrow PB, Jennings PA: Depression of cell-mediated immunity by tumour cell products: induction of resistance by immunotherapeutically active extracts of bovine ocular squamous cell carcinoma 231
Nicolin A → Canti G, et al. 64
Nilsonne U → Vánky F, et al. 180
Noguchi PD → Leong SPL, et al. 106
Nojima S → Naito M, et al. 158
Nomoto K → Hashimoto S, et al. 1
Nomura H → Naito M, et al. 158
Nunziata C → Tentori L, et al. 86

Ogata M → Yoshioka T, et al. 8
Oh-hashi F, Kataoka T, Taniyama T: I-A^d antigen expression of pyran copolymer-induced peritoneal cells in tumor vaccine-primed mice and its association with the host antitumor response 57
Oriandi R → Ripamonti M, et al. 13
Oskam R → De Weger RA, et al. 25
Overton RW → Peppoloni S, et al. 49
Ozaki A → Ishihara J, et al. 185

Pačovský Z → Munzarová M, et al. 272
Parmiani G → Grazioli L, et al. 237
Parnell GD → Eccles SA, et al. 37
Pattengale PK → Fujimiya Y, et al. 213
Pedersen L, Rose C, Langvad E: Combined treatment of advanced malignant melanoma with coumarin and cimetidine. A phase II study 178
Peppoloni S, Mathieson BJ, Herberman RB, Overton RW, Gorelik E: In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets 49
Péterffy Á → Vánky F, et al. 180
Pommier GJ, Garrouste FL, Bettetini D, Culouscou JM, Remacle-Bonnet MM: In vivo delayed rejection of tumors and inhibition of delayed – type hypersensitivity by HT-29 human colonic adenocarcinoma cell line 225
Poste G → Bugelski PJ, et al. 93
Preffer FI → Kradin RL, et al. 76
Purvies HP → Eccles SA, et al. 37

Ramshaw IA → Hoon DSB, et al. 42

Ravikumar T → Wu J, et al. 68
Rejthar A → Munzarová M, et al. 272
Remacle-Bonnet MM → Pommier GJ, et al. 225
Ricci L → Canti G, et al. 64
Rilke F → Ripamonti M, et al. 13
Rinehart J, LaForge J, Gochnour D, Neidhart J: Phase II trial of MVE-II in metastic malignant melanoma 244
Ripamonti M, Canevari S, Ménard S, Mezzanzanica D, Miotti S, Orlandi R, Rilke F, Tagliabue E, Colnaghi MI: Human carcinoma cell lines xenografted in athymic mice: biological and antigenic characteristics of an intraabdominal model 13
Rohde-Schulz B → Masihi KN, et al. 19
Rosales C → Steplewski Z, et al. 197
Rose C → Pedersen L, et al. 178
Roselli M → Tentori L, et al. 86
Roth JA → Leong SPL, et al. 106
Ryde PJ → Corvalan JRF, et al. 138

Saccavini J-C → Dazord L, et al. 263
Saijo N → Ishihara J, et al. 185
Sakurai M → Ishihara J, et al. 185
Sasaki T → Uchida H, et al. 207
Sasaki Y → Ishihara J, et al. 185
Sato S → Fujiwara H, et al. 113
Sato S, Fujiwara H, Kosugi A, Hamaoka T: Studies on the recovery from tolerance to tumor antigens. II. Accelerated recovery of tumor-specific effector T cells in tolerant mice by applying T-T cell interaction mechanism 121
Sensi M → Grazioli L, et al. 237
Shau H → Agah R, et al. 247
Shimizu J → Yoshioka T, et al. 8
Smith W → Corvalan JRF 127
Smith W → Corvalan JRF, et al. 133
Smith W → Corvalan JRF, et al. 138
Sonis S → Wu J, et al. 68
Sorg C → Matzku S, et al. 151
Spradbrow PB → Nelson M, et al. 231
Steplewsky Z, Jeglum KA, Rosales C, Weintraub N: Canine lymphoma-associated antigens defined by murine monoclonal antibodies 197
Strander H → Einhorn S, et al. 190
Strauss HW → Kradin RL, et al. 76
Styles JM → Eccles SA, et al. 37

Tagliabue E → Ripamonti M, et al. 13
Takahashi H → Ishihara J, et al. 185
Takahashi T → Ishihara J, et al. 185
Takai Y → Yoshioka T, et al. 8
Takami T → Leong SPL, et al. 106
Takasuka N → Uchida H, et al. 207
Taniyama T → Oh-hashi F, et al. 57
Tentori L, Fuggetta MP, D'Atri S, Aquino A, Nunziata C, Roselli M, Ballatore P, Bonmassar E, De Vecchis L: Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy 86
Toujas L → Dazord L, et al. 263
Tsuji H → Akiyoshi T, et al. 259
Tsushima S → Naito M, et al. 158

Uchida H, Sasaki T, Uchida NA, Takasuka N, Endo Y, Kamiya H: Oncostatic and immunomodulatory effects of a glycoprotein fraction from water extract of abalone, *Haliotis discus hannai* 207
Uchida NA → Uchida H, et al. 207

Vánky F, Klein E, Willems J, Böök K, Ivert T, Péterffy Á, Nilsonne U, Kreicbergs A: Lysis of autologous tumor cells by blood lymphocytes activated in autologous mixed lymphocyte tumor cell culture – no correlation with the postsurgical clinical course 180

Wahl RL, Wilson BS, Liebert M, Beierwaltes WH: High-dose, unlabeled, nonspecific antibody pretreatment: influence on specific antibody localization to human melanoma xenografts 221
Wasserman J → Einhorn S, et al. 190
Weintraub N → Steplewski, et al. 197
Wilbrink B → De Weger RA, et al. 25
Willems J → Vánky F, et al. 180
Wilson BS → Wahl RL, et al. 221
Wilson R → Wu J, et al. 68
Wu J, Fitzgerald J, Sonis S, Ravikumar T, Wilson R: Increased efficiency of immunotherapy using irradiated tumor cells 68

Yokokura T → Bugelski PJ, et al. 99
Yokokura T → Hashimoto S, et al. 1
Yokokura T → Matsuzaki T, et al. 99
Yoshioka T, Fujiwara H, Takai Y, Ogata M, Shimizu J, Hamaoka T: The role of tumor-specific Lyt-1$^+$2$^-$ T cells in eradicating tumor cells in vivo. II. Lyt-1$^+$2$^-$ T-cells have potential to reject antigenically irrelevant (bystander) tumor cells on activation with the specific target tumor cells 8

Zemanová D → Munzarová M, et al. 272

Subject index of volume 24

Abalone 207
Antibody
- anti-CEA 202
- localization 221
- monoclonal 13, 144, 151, 197, 263
- monoclonal hybrid-hybrid 127, 138
Antigen
- B16-melanoma-associated 106
- canine lymphoma associated 197
- carcinoembryonic 127, 133
- HLA-DR 272
- Ia expression 57

Bone marrow
- reconstitution 113
Breast cancer 72, 86

Cell cycle 106
Chemotherapy 86
Cholesteryl hemisuccinate 272
Cimetidine 178
Corynebacterium parvum 1
Coumarin 178
Cyclophosphamide 49
Cytotoxic factor 1

Drug targeting 133, 138

Endotoxins 165

Ganglioside GD_3 144

Immunity
- tumor 8, 25, 42, 49, 64, 231
Immunopotentiation 57
Immunotherapy 68, 76, 178, 269
Immunotoxin 37, 202
Interferon 86, 190
Interleukin-2 76, 247, 269

Lactobacillus casei 1, 99
LAK cells 247, 269
Leukemia 213
Liposomes
- glyceroglycolipid 158
Lung cancer 76, 263
Lymphocyte 144, 180, 259
Lymphoma
- canine 197
- murine 25
Lysosome 247

Macrophage 1, 25, 93, 158, 207
Melanoma 144, 151
- B16-BL6 99
- B16-associated antigen 106
- human xenografts 221
- malignant 178, 244, 272
Metastasis 42, 93, 99
Mitomycin C 259
Monoclonal antibodies 13, 144, 151, 197, 263
- hybrid-hybrid 127, 138
Muramyl dipeptide 19
MVE-11 244, 253

NK-cells 19, 72, 86, 213, 253

OK-432 172
Ovarian cancer 172

Poly A:U 165

Ricin B chain 37

T cells 8, 49, 113, 121, 237
Trehalose dimycolate 19
Tumor type
- breast 72, 86
- colonic 225
- gynecological 190
- leukemia 213
- lung 76, 263
- melanoma 99, 106, 144, 151, 178, 221, 244, 272
- ocular carcinoma, bovine 231
- ovarian 172

Vinca alkaloids 127, 133, 138